Annual Report 2023

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2023 87 The United Laboratories International Holdings Limited Annual Report 2023 5. REVENUE AND SEGMENT INFORMATION (Continued) Segment information (Continued) (b) Other segment information Amounts included in the measurement of segment profit or loss: For the year ended 31 December 2023 Intermediate Bulk Finished products medicine products Unallocated Consolidated RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 Amortisation of intangible assets 2,031 – 15,416 – 17,447 Depreciation of right-of-use assets 3,324 5,270 2,874 430 11,898 Depreciation of property, plant and equipment 388,205 87,827 60,198 73 536,303 Net loss on disposal of property, plant and equipment 1,603 1,151 949 – 3,703 Written off of property, plant and equipment 23,454 22,737 1,764 – 47,955 Impairment losses (reversed) recognised (1,216) (1,688) 1,494 (552) (1,962)